Evaluation of immunoassays for the detection and typing of PCR amplified human papillomavirus DNA

S Venturoli, M Zerbini, M La Placa Jr, A D'Antuono, M Negosanti, G Gentilomi, G Gallinella, E Manaresi, M Musiani

Abstract

Aims—To evaluate different hybridisation techniques to detect and type human papillomavirus (HPV) DNAs amplified by consensus primer polymerase chain reaction (PCR) in biopsy and cytological specimens.

Methods—A hybrid capture-immunoassay in microtitre wells was performed to detect HPV sequences amplified by PCR and typed by specific oligoprobes. Consensus primers were used to amplify a sequence within the L1 open reading frame, and direct digoxigenin labelling of amplified products was performed during the amplification reaction. The amplified product was separately hybridised with six biotinylated type specific probes (HPV6, 11, 16, 18, 31, and 33); hybrids were then captured into streptavidin coated microtitre wells and detected by a spectrophotometer as an ELISA using antidigoxigenin Fab fragment labelled with peroxidase and a colorimetric substrate. The results were compared with the dot-blot immunoassay used to detect and type PCR amplified HPV DNA sequences. Consensus primers were used to generate the same unlabelled PCR product; digoxigenin labelled type specific probes for HPV6, 11, 16, 18, 31, and 33 were used and hybrids visualised by colorimetric immunoenzymatic reaction. Thirty nine biopsy specimens and 31 cytological samples were tested by the PCR-ELISA and by standard PCR followed by dot-blot hybridisation.

Results—The PCR-ELISA proved to be more sensitive than standard PCR with dot-blot hybridisation typing. All samples positive for HPV-DNA in standard PCR with dot-blot hybridisation method were confirmed positive by the PCR-ELISA assay; however, seven samples were positive only by PCR-ELISA.

Conclusions—The PCR-ELISA assay, which can be performed in one day, is easily standardised and therefore seems to be a practical, sensitive, and reliable diagnostic tool for the detection and typing of HPV genomes in biopsy and in cytological specimens in the routine diagnostic laboratory.

(J Clin Pathol 1998;51:143-148)

Human papillomavirus (HPV) infections are related to several cutaneous and mucosal dysplasias, including both benign and malignant lesions.¹⁻⁸ The HPVs are commonly referred to as high, intermediate or low oncogenic risk, depending on the frequency with which they are associated with malignancy. The high risk types include HPV16, 18, 45, and 56; HPV31, 33, and 35 are intermediate risk types; and HPV6, 11, 42, 43, and 44 are low risk.

As HPVs cannot be propagated in cell cultures, and only small amounts of viral antigens are present in body fluids,⁹ the diagnosis of HPV infection mainly relies on HPV nucleic acid detection.¹⁰ The most common methods used to detect and type HPV DNAs are: Southern blot,^{11 12} dot-blot,¹³ in situ hybridisation (ISH),^{14 15} and polymerase chain reaction (PCR).

Nucleic acid amplification techniques such as PCR¹⁶ are valid tools for the diagnosis of HPV related diseases.¹⁷ In fact PCR amplification allows rapid and specific detection of low abundance viruses and a single genome copy can be detected in clinical specimens. Many PCR protocols use either primers recognising specific HPV open reading frames (ORFs)¹⁸ or common highly conserved sequences among different HPV types.^{19 20} Typing of HPV DNA generated by PCR with consensus primers can be performed by restriction fragment length polymorphism,²¹ by direct DNA sequence analysis,²² and by dot-blot hybridisation with type specific probes.²³ Several hybrid capture immunoassays have recently been developed for the detection and typing of PCR products.²⁴⁻²⁹

In this study a hybridisation capture assay in microplates was compared to dot-blot hybridisation for the detection and typing of PCR amplified HPV DNAs in 39 paraffin wax embedded biopsies and 31 cytological specimens.

Methods

CLINICAL SPECIMENS

Ten micrometer sections were cut from 39 paraffin wax embedded biopsy samples. Tissue specimens were selected according to clinical, histological, and/or histochemical findings: 3 were classified as warts, 7 as genital condylomas, 1 as Bushke-Lowenstein tumour, 5 as cervical intraepithelial neoplasias (CIN I and CIN II), 3 as epithelial lesions of the penis, 6 as squamous cell carcinomas, 3 as cutaneous

Department of Clinical and Experimental Medicine, Division of Microbiology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
S Venturoli
M Zerbini
G Gentilomi
G Gallinella
E Manaresi
M Musiani

Division of Dermatology, University of Bologna
M La Placa Jr
A D'Antuono
M Negosanti

Correspondence to:
Dr Zerbini.
email: mzerbini@med.unibo.it

Accepted for publication
11 November 1997

Keywords: human papillomavirus; polymerase chain reaction; typing

Bowen's disease, 2 as bowenoid papulosis, 2 as verrucous carcinomas, 1 as laryngeal lesion, 1 as tongue condyloma, 3 as papular lesions in epidermodysplasia verruciformis, and 2 as gastric papillomas.

Thirty one cervical scrapes were selected according to clinical, colposcopic, cytological, and/or histochemical findings: 3 were classified as cervical condylomas, 18 as CIN I, 6 as CIN II, and 4 as CIN III.

All 70 clinical specimens and 4 reference clinical specimens negative for HPV DNAs were tested either by standard PCR¹⁹ with dot-blot hybridisation²³ or by the PCR-ELISA method.

SPECIFICITY AND SENSITIVITY CONTROLS

The cervical carcinoma cell line CaSki, which contains 500–600 HPV16 DNA copies per cell, and HeLa, which contains 20–50 HPV18 DNA copies per cell, were used as positive controls. To determine the sensitivity of standard PCR dot-blot hybridisation and the PCR-ELISA method, 10-fold dilutions up to 10⁻⁶ of 10³ HeLa or CaSki cell lysates were tested.

Four paraffin wax embedded biopsy specimens, analysed by ISH (Kreatech, the Netherlands) with subgenomic type specific probes and proved positive for HPV6, 11, 31, and 33 respectively, were used as positive controls. The biopsies were dewaxed and digested as described below. Then end point dilutions of the lysates were performed and tested by standard PCR with dot-blot hybridisation. The highest dilution, which proved positive by standard PCR with dot-blot hybridisation, was introduced as a reference positive control for the PCR-ELISA method.

Human fibroblast cell line MRC-5 was used as a negative control. Ten microliters of 10³ MRC-5 cell lysate were processed. In addition, reference specimens from four paraffin wax embedded cutaneous biopsies unrelated to HPV induced lesions and negative for HPV DNAs were analysed. The values obtained for the MRC-5 negative control by PCR-ELISA were in the range of the values obtained for reference specimens negative for HPV DNAs ($p < 0.01$).

DNA PREPARATION

Paraffin wax embedded sections from biopsy specimens were dewaxed twice in xylene, dehydrated in absolute ethanol, and protease digested by incubation at 55°C for two hours in 200 µl of digestion buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3, 0.05% Tween 20 and 400 µg/ml of proteinase K), followed by heat inactivation at 95°C for 10 minutes.

Cytological specimens from cervical scrapes were collected in phosphate buffered saline (PBS), centrifuged, and the pellets digested with buffer as described above.

Confluent monolayers from HeLa, CaSki, and MRC-5 cell lines were harvested by trypsinisation, washed with PBS, and spun down. The pellet was digested with buffer as described above.

PRIMERS AND PROBES

Consensus primer pair MY09 and MY11,¹⁹ able to detect more than 25 different HPV types within the L1 ORF, were used in PCR amplification.

Oligonucleotide probes MY12, MY13, MY14, WD74, WD128, and MY59²³ specific to the L1 PCR products of HPV6, 11, 16, 18, 31, and 33, respectively, were used in hybridisation reactions.

As amplification control, primers GH20 and PC04,³⁰ recognising human β globin gene sequence, were used in each PCR reaction and amplified products were detected by PC03 probe.

All the hybridisation probes used in the PCR-ELISA method were 5' labelled with biotin, while all hybridisation probes used in standard PCR with dot-blot hybridisation were 5' labelled with digoxigenin.

STANDARD PCR AND DOT-BLOT HYBRIDISATION

Standard PCR was performed simultaneously for amplification of HPV sequences and human β globin sequence. HPVs were amplified by consensus primers.¹⁹ Amplification products were visualised through 2% agarose gel with ethidium bromide staining and were then analysed by dot-blot hybridisation²³ with digoxigenin labelled internal probes specifically for HPV types 6, 11, 16, 18, 31, and 33. Hybridised digoxigenin labelled probes were then visualised colorimetrically by immunoenzymatic reaction using antidigoxigenin Fab fragments labelled with alkaline phosphatase.³¹

PCR-ELISA METHOD

DNA amplification and labelling

DNA amplification and labelling was performed in 50 µl PCR reaction volume containing 50 mM KCl, 10 mM Tris-HCl pH 8.2, 4 mM MgCl₂, 0.1 mM dATP, 0.1 mM dGTP, 0.1 mM dCTP, 0.095 mM dTTP, 0.005 mM digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany), 0.1 µM each primer MY09, MY11, GH20, and PC04, 2.5 Units Taq DNA polymerase, and 10 µl of each digested sample.

After an initial denaturation step at 95°C for five minutes, 40 cycles were performed of one minute at 95°C, one minute at 55°C, two minutes at 72°C, followed by a final extension step of five minutes at 72°C.

Hybridisation and detection reaction

Amplified products, labelled with digoxigenin during the amplification reaction, were separately hybridised with type specific biotinylated probes for HPV6, 11, 16, 18, 31, and 33, and with biotinylated probe for human β globin gene sequence. A volume of 5 µl of amplified product was added to 5 µl of denaturing solution (100 mM NaOH, 0.1% Tween-20) and incubated at 25°C for 10 minutes. Then 190 µl of hybridisation solution (300 mM NaCl, 100 mM Tris-HCl pH 6.5, 10 mM EDTA, 0.1% Tween-20), containing 2 pmol/ml of a type specific probe were added and hybridisation was performed at 55°C for 10 minutes. Each reaction volume was transferred

Figure 1 PCR products obtained from 10-fold dilutions of 10^3 HeLa (A) or CaSki (B) cell lysates hybridised with four different concentrations (1, 2, 5, and 10 pmol/ml) of type specific probe (WD74 and MY14). The hybrids were captured in microtitre plate wells.

to a streptavidin coated microtitre plate well (Boehringer Mannheim) and incubated at 25°C for 50 minutes. Plates were then washed five times with TBST (150 mM NaCl, 100 mM Tris-HCl pH 7.5, 0.1% Tween-20). A volume of 200 μ l of antidigoxigenin POD conjugated solution (10 mU/ml in TBST) (Boehringer Mannheim) was added and incubated at 25°C for 30 minutes. After washing five times in TBST, 200 μ l of ABTS substrate solution was added to each well, and developed for 30 minutes at room temperature. The colorimetric reaction was measured by spectrophotometry at the optical density (OD) of 405 nm.

As the values of the MRC-5 negative control were in the range of values obtained for reference negative specimens, the cut off of the reaction was determined as twice the mean value of a negative MRC-5 control tested in triplicate. This corresponds to the OD value obtained from HeLa and CaSki cell lysates containing 20–50 copies of HPV18 DNA and 50–60 copies of HPV16 DNA, respectively. Test samples with values in the range of $\pm 20\%$ of the cut off value were retested.

Results were expressed as net absorbance after the absorbance of the buffer blank was subtracted and index value was calculated as OD of the sample/cut off; index value > 1 was considered positive.

Figure 2 PCR products obtained from 10-fold dilutions of 10^3 HeLa or CaSki cell lysates were hybridised with WD74 and MY14 probes, respectively. The hybrids were captured in microtitre plate wells.

Results

To determine the optimum amount of type specific probes to use in the hybridisation reaction, four different concentrations (1, 2, 5, and 10 pmol/ml) of WD74 or MY14 probes specific for HPV18 and HPV16, respectively, were hybridised with PCR amplified products obtained from 10-fold dilutions of 10^3 HeLa (fig 1A) or CaSki (fig 1B) cell lysates, respectively.

The hybridisation signal reached the maximum value when a concentration of 2 pmol/ml of each probe was used at the different concentrations of HeLa or CaSki cells tested. The signal remained constant even at higher probe concentrations. Therefore a probe concentration of 2 pmol/ml was used in all the experiments.

To determine the sensitivity of the reaction, a lysate from 10^3 HeLa or CaSki cells was diluted up to 10^{-6} and amplified by PCR. Hybridisation and capture assay of amplified products proved positive up to 10^{-4} for CaSki (about 50–60 genome copies) and up to 10^{-3} for HeLa cells (about 20–50 genome copies) (fig 2). When the same dilutions of HeLa and CaSki cell lysates were amplified by standard PCR and detected with digoxigenin labelled specific probes, the assay proved positive up to 10^{-3} for CaSki cells and up to 10^{-2} for HeLa cells.

The specificity of the PCR-ELISA was assessed on MRC-5 cell lysate. No amplified products were detected when PCR treated MRC-5 cell lysate was hybridised with type specific probes for HPV6, 11, 16, 18, 31, and 33, and captured in a microtitre plate well. No cross reactions were observed when amplified products from HeLa were hybridised with MY12, MY13, MY14, WD128, MY59 specific for HPV6, 11, 16, 31, and 33, respectively, and amplified products from CaSki were hybridised with MY12, MY13, WD74, WD128, MY59 specific for HPV6, 11, 18, 31, and 33, respectively (data not shown).

To test the reproducibility of the PCR assay, dilutions from HeLa and CaSki cell lysates were amplified in three independent PCR assays and amplified products detected by the ELISA method in the same plate. The difference observed in OD values between replicate PCR samples was assessed at about 4%.

Table 1 HPV detection and typing in paraffin wax embedded biopsy specimens

Sample	Diagnosis	PCR dot-blot	PCR-ELISA	Index value
1	Vulvar condyloma	HPV6	HPV6	1.04
2	Vulvar condyloma	HPV6	HPV6	1.23
3	Vulvar condyloma	HPV6	HPV6	7.04
4	Bushke-Lowenstein tumour	HPV6	HPV6	4.33
5	Wart	HPV6	HPV6	1.46
		HPV11	HPV11	2.84
6	Vulvar condyloma	HPV11	HPV11	1.29
7	Vulvar condyloma	HPV11	HPV11	1.14
8	Periungueal squamous cell carcinoma	HPV16	HPV16	4.74
9	Cutaneous Bowen's disease	HPV16	HPV16	4.20
10	Cutaneous Bowen's disease	HPV16	HPV16	3.66
11	Cutaneous Bowen's disease	HPV16	HPV16	5.36
12	Vulvar condyloma	HPV16	HPV16	8.38
13	Gastric papilloma	HPV16	HPV16	9.87
14	Gastric papilloma	HPV16	HPV16	3.88
15	CIN II	HPV16	HPV16	3.46
16	CIN II	HPV33	HPV33	5.68
17	Vulvar condyloma	Negative	HPV6	1.14
18	Bowenoid papulosis	Negative	HPV16	2.00
19	Subungueal squamous cell carcinoma	Negative	HPV16	1.86
20	Bowenoid papulosis	Negative	HPV18	1.30
21	Verrucous carcinoma	Negative	HPV33	1.44
22	Laryngeal lesion	Negative	Negative	
23	Periungueal squamous cell carcinoma	Negative	Negative	
24	Wart	Negative	Negative	
25	Periungueal squamous cell carcinoma	Negative	Negative	
26	Subungueal squamous cell carcinoma	Negative	Negative	
27	Subungueal squamous cell carcinoma	Negative	Negative	
28	Wart	Negative	Negative	
29	Papular lesion in epidermodysplasia verruciformis	Negative	Negative	
30	Papular lesion in epidermodysplasia verruciformis	Negative	Negative	
31	Papular lesion in epidermodysplasia verruciformis	Negative	Negative	
32	Tongue condyloma	Negative	Negative	
33	Verrucous carcinoma	Negative	Negative	
34	CIN I	Negative	Negative	
35	CIN II	Negative	Negative	
36	CIN II	Negative	Negative	
37	Epithelial lesion of penis	Negative	Negative	
38	Epithelial lesion of penis	Negative	Negative	
39	Epithelial lesion of penis	Negative	Negative	

HPV genotyping was performed with probes specific for HPV6, 11, 16, 18, 31, and 33. Index value was calculated as optical density of the sample/cut off in each microtitre plate.

Table 2 HPV detection and typing in cytological specimens

Sample	Diagnosis	PCR dot blot	PCR-ELISA	Index value
1	Cervical condyloma	HPV6	HPV6	8.56
2	Cervical condyloma	HPV16	HPV 16	4.24
3	Cervical condyloma	HPV16	HPV 16	1.90
4	CIN I	HPV16	HPV16	4.53
5	CIN I	HPV16	HPV16	3.76
6	CIN I	HPV16	HPV16	2.43
7	CIN II	HPV16	HPV16	1.76
8	CIN III	HPV16	HPV16	2.16
9	CIN I	HPV31	HPV31	8.32
10	CIN I	HPV31	HPV31	3.54
11	CIN I	HPV31	HPV31	2.33
12	CIN II	HPV31	HPV31	4.56
13	CIN II	HPV31	HPV31	3.12
14	CIN I	HPV33	HPV33	2.47
15	CIN II	HPV33	HPV33	1.68
16	CIN III	HPV33	HPV33	7.44
17	CIN III	HPV33	HPV33	3.01
18	CIN III	HPV33	HPV33	3.18
19	CIN II	Negative	HPV6	1.24
20	CIN I	Negative	HPV31	1.19
21	CIN I	Negative	Negative	
22	CIN I	Negative	Negative	
23	CIN I	Negative	Negative	
24	CIN I	Negative	Negative	
25	CIN I	Negative	Negative	
26	CIN I	Negative	Negative	
27	CIN I	Negative	Negative	
28	CIN I	Negative	Negative	
29	CIN I	Negative	Negative	
30	CIN I	Negative	Negative	
31	CIN II	Negative	Negative	

HPV genotyping was performed with probes specific for HPV6, 11, 16, 18, 31, and 33. Index value was calculated as optical density of the sample/cut off in each microtitre plate.

To measure the reproducibility of the ELISA method, dilutions from HeLa and CaSki cell lysates were amplified in PCR and hybridised with specific probes. The hybrids were captured in three different streptavidin coated wells and the difference observed in OD values between replicate samples was assessed at about 2%.

As positive controls for HPV DNAs types 16 and 18, CaSki and HeLa cell lysates were used in the experiments at dilutions of 10^{-3} and 10^{-2} , respectively. In addition, reference clinical specimens positive for HPV DNAs types 6, 11, 31, and 33 were used at 10^{-3} , 10^{-3} , 10^{-4} , and 10^{-4} , respectively.

Thirty nine paraffin wax embedded tissue specimens and 31 cytological specimens were tested by the PCR-ELISA method. All the specimens had previously been analysed by standard PCR and typed by dot-blot hybridisation with specific probes. With the standard technique, 23 samples had proved negative for HPV6, 11, 16, 18, 31, and 33, and 16 had proved positive for HPV DNAs (table 1). Of the cytological samples tested, 13 were negative and 18 positive (table 2).

With the PCR-ELISA method 18 of the 39 biopsy specimens analysed proved negative for HPV DNAs, and 21 proved positive (table 1). Eleven of the 31 cytological specimens analysed proved negative for HPV DNAs and 20 proved positive (table 2). All biopsy and cytological specimens were positive for human β globin gene sequence.

Reference positive controls proved positive in each experiment with both methods tested. Four reference negative biopsies proved negative both by standard PCR with dot-blot hybridisation and by the PCR-ELISA method. No cross contaminations from microtome cut were detected—paraffin slices treated as clinical specimens proved negative for HPV6, 11, 16, 18, 31, and 33 DNA, and there was no contamination during PCR amplification tested by the presence of MRC-5 negative controls and blank samples (PCR reagents without a DNA template) run in each assay.

To test the reproducibility of the results, three positive and two negative clinical specimens by the PCR-ELISA were retested in three independent assays and the results were confirmed.

All samples positive for HPV DNA by standard PCR with dot-blot hybridisation method were confirmed positive in the PCR-ELISA assay; however, seven samples were positive only by PCR-ELISA: 2 were identified as HPV6, 2 as HPV16, 1 as HPV18, 1 as HPV31, and 1 as HPV33.

Discussion

Several diagnostic techniques have been used for the diagnosis of HPV infections. Currently PCR assay offers the greatest sensitivity and the use of consensus primers allows the amplification of a broad spectrum of HPV types.^{19 20 32} Many technical strategies have been developed to type and quantify HPV DNA sequences amplified by consensus primers.^{27 33-39}

We evaluated a semiquantitative method to detect and type HPV amplified sequences, this method, able to give an objective evaluation of the results, was compared with dot-blot hybridisation.

In the PCR-ELISA, the well conserved L1 region of the HPV genome was amplified by consensus primers and directly labelled with digoxigenin during amplification reaction. The direct incorporation of a labelled nucleotide during amplification reaction increases the sensitivity of the assay with respect to extension labelling primers, giving a more efficient labelling.²⁴ In fact, one digoxigenin-dUTP is incorporated approximately every 20 dTTPs into an amplified region of 450 base pairs.

The specificity and typing of amplified products was assured by biotinylated oligoprobes specific for HPV16, 18, 31, 33, 6, and 11, considered at high, intermediate, and low risk for their oncogenic potential. This method, however, can be adapted to the detection of all HPV genotypes and represents a valid tool to study the pathogenicity of the different genotypes.

The PCR-ELISA method can be adapted to screen HPV DNA positive clinical samples using MY18 and MY57 generic probes,²³ but in our experience the assay proved less sensitive with degenerated probes (data not shown). Furthermore, a second hybridisation reaction to identify type specific HPV DNAs is necessary. However, if the diagnosis of the laboratory can be limited to detect HPV DNAs and discriminate the oncogenic potential of HPVs, the use of two cocktails of oligonucleotide probes can be used to recognise high and low risk HPVs.²⁷⁻³⁹ This method is less time consuming and technically demanding but it allows only a limited reduction of costs as the cost is mainly attributable to the probes.

Digoxigenin labelled PCR products, hybridised with specific biotinylated probes, were captured into streptavidin coated microtitre wells by a biotin-streptavidin binding and detected by an immunoenzymatic reaction.²⁹ The colorimetric reaction was automatically detected by spectrophotometry and semiquantitative determination of HPV type specific DNA was achieved by comparison with positive reference samples. Of the 39 biopsy specimens and the 31 cytological scrapes tested, 18 and 11, respectively proved negative by both the PCR-ELISA and standard method. These results could indicate that the clinical diagnosis does not always correlate with the laboratory investigation. Otherwise HPV genotypes other than those investigated could be present.

When the 70 clinical specimens were tested both by the PCR-ELISA and the standard PCR with dot-blot hybridisation, seven samples were positive by the PCR-ELISA only. The discrepancy of the results could be interpreted as a higher sensitivity for the PCR-ELISA than standard PCR with dot-blot hybridisation, probably because of the higher efficiency of the labelling method used.

With the PCR-ELISA, evaluation of results is objective and semiquantitative data can be

obtained, while dot-blot hybridisation requires a subjective interpretation and, at low viral concentration, the interpretation of the results could be doubtful.

The possibility of obtaining semiquantitative data by the PCR-ELISA is particularly useful as the viral load seems to predict the clinical course of the infection and is implicated in maternal-infant transmission.³⁵⁻⁴⁰

This assay can be performed in one day, is easily standardised and therefore seems to be a practical, sensitive, and reliable diagnostic tool for the detection and typing of HPV genomes in biopsy and cytological specimens in the routine diagnostic laboratory.

The skilful technical help of Ms Marinella Plazzi and Ms Consuelo Corsini is gratefully acknowledged. This work was partially supported by a Ministry of University and Scientific Research grant and by the University of Bologna Funds for selected research topics and by CNR Target Project Biotechnology.

- Abramson AL, Brandsma JL, Steinberg BM, *et al.* Verrucous carcinoma on the larynx. Possible human papillomavirus etiology. *Arch Otolaryngol* 1985;111:709-15.
- de Villiers EM. Heterogeneity of the human papillomavirus group. *J Virol* 1989;63:4898-903.
- Howley PM. The role of papillomavirus in human cancer. In: De Vita VC Jr, Hellman S, Rosenberg SA, eds. *Important advances in oncology*. Philadelphia: Lippincott, 1987:55-73.
- Löning T, Ikenberg H, Becker J, *et al.* Analysis of oral papillomas, leukoplakias, and invasive carcinomas for human papillomavirus type related DNA. *J Invest Dermatol* 1985;84:417-20.
- Schwartz RA, Janninger CK. Bowenoid papulosis. *J Am Acad Dermatol* 1991;24(2 pt 1):261-4.
- Tosti A, La Placa M, Fanti P, *et al.* Human papillomavirus type 16 associated periungual squamous cell carcinoma in a patient with acquired immunodeficiency syndrome. *Acta Derm Venereol* 1994;74:478-9.
- Tyan YS, Liu ST, Ong WR, *et al.* Detection of Epstein Barr virus and human papillomavirus in head and neck tumors. *J Clin Microbiol* 1993;31:53-6.
- zur Hausen H. Human papillomavirus in the pathogenesis of anogenital cancer. *Virology* 1991;184:9-13.
- Bennet Jensen A, Kurman RJ, Lancaster WD. Detection of human papillomavirus common antigens in lesions of skin and mucosa. *Clin Dermatol* 1985;3:56-63.
- Schneider A. Methods for detection of human papillomaviruses. In: Syrjänen K, Gissmann Koss L, eds. *Papillomaviruses and human disease*. Heidelberg: Springer-Verlag, 1987:19-39.
- Brandsma J, Burk RD, Lancaster WD, *et al.* Inter-laboratory variation as an explanation for varying prevalence estimates of human papillomavirus infection. *Int J Cancer* 1989;43:260-2.
- Roman A, Fife KH. Human papillomaviruses: are we ready to type? *Clin Microbiol Rev* 1989;2:166-90.
- Cornelissen MTE, van der Velden KJ, Walboomers JM, *et al.* Evaluation of different DNA-DNA hybridization techniques in detection of HPV16 DNA in cervical smears and biopsies. *J Med Virol* 1988;25:105-14.
- Beckmann AM, Myerson D, Daling JR, *et al.* Detection and localization of human papillomavirus DNA in human genital condylomas by in situ hybridization with biotinylated probes. *J Med Virol* 1985;16:265-78.
- Park RS, Kurman RJ, Keissis TD, *et al.* Comparison of peroxidase labeled DNA probes with radioactive RNA probes for detection of human papillomaviruses by in situ hybridization in paraffin sections. *Mod Pathol* 1991;4:81-5.
- Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. *Methods Enzymol* 1987;35:335-50.
- Hildesheim A, Schiffman MH, Gravitt PE, *et al.* Persistence of type-specific human papillomavirus infection among cytologically normal women. *J Infect Dis* 1994;169:235-40.
- Cornelissen MTE, van den Tweel JG, Struyck APHB, *et al.* Localization of human papillomavirus type 16 DNA using the polymerase chain reaction in the cervix uteri of women with cervical intraepithelial neoplasia. *J Gen Virol* 1989;70:2555-62.
- Manos MM, Ting Y, Wright DK, *et al.* Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. *Cancer Cells* 1989;7:209-14.
- Snijders PJF, van den Brule AJC, Schrijnemakers HJF, *et al.* The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. *J Gen Virol* 1990;71:173-81.
- Contorni M, Leoncini P. Typing of human papillomavirus DNAs by restriction endonuclease mapping of the PCR products. *J Virol Methods* 1993;41:29-36.
- Smits HL, Tieben LM, Tjong-A-Hung SP, *et al.* Detection and typing of human papillomavirus present in fixed and

- stained archival cervical smears by a consensus polymerase chain reaction and direct sequence analysis allow the identification of a broad spectrum of human papillomavirus types. *J Gen Virol* 1992;73:3263-8.
- 23 Resnick RM, Cornelissen MTE, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. *J Nat Cancer Inst* 1990;82:1477-84.
  - 24 Adams V, Moll C, Schmid M, et al. Detection and typing of human papillomavirus in biopsy and cytological specimens by polymerase chain reaction and restriction enzyme analysis. A method suitable for semiautomation. *J Med Virol* 1996;48:161-70.
  - 25 Cox JT, Lorincz AT, Schiffman MH, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. *Am J Obstet Gynecol* 1995;172:946-54.
  - 26 Gibellini D, Zerbini M, Musiani M, et al. Microplate capture hybridization of amplified parvovirus B19 DNA fragment labelled with digoxigenin. *Mol Cell Probes* 1993;7:453-8.
  - 27 Jacobs MV, de Roda Husman AM, van den Brule AJC, et al. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. *J Clin Microbiol* 1995;33:901-5.
  - 28 Poljak M, Seme K. Rapid detection and typing of human papillomaviruses by consensus polymerase chain reaction and enzyme-linked immunosorbent assay. *J Virol Methods* 1996;56:231-8.
  - 29 Zerbini M, Gibellini D, Musiani M, et al. Automated detection of digoxigenin-labelled B19 parvovirus amplicons by a capture hybridization assay. *J Virol Methods* 1995;55:1-9.
  - 30 Saiki RK, Scharf S, Faloona FA, et al. Enzymatic amplification of a β -globin genomic sequence and restriction site analysis for diagnosis of sickle cell anemia. *Science* 1985;230:1350-4.
  - 31 Zerbini M, Musiani M, Venturoli S, et al. Rapid screening for B19 parvovirus DNA in clinical specimens with a digoxigenin-labeled DNA hybridization probe. *J Clin Microbiol* 1990;28:2496-9.
  - 32 Gregoire L, Arella M, Campione-Piccardo J, et al. Amplification of human papillomavirus DNA sequences by using conserved primers. *J Clin Microbiol* 1989;27:2660-5.
  - 33 Bavin PJ, Giles JA, Deery A, et al. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. *Br J Cancer* 1993;67:602-5.
  - 34 Lungu O, Wei Sun X, Wright TC, et al. A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors. *Obstet Gynecol* 1995;85:337-42.
  - 35 Morrison EAB, Burk RD. PCR detection of human papillomavirus: quantitation may improve clinical utility. In: Becker Y, Darai G, eds. *PCR protocols for diagnosis of human and animal virus diseases*. Heidelberg: Springer-Verlag, 1995:279-86.
  - 36 Venuti A, Badaracco G, Marcante ML. Detection and typing of human papillomavirus by single hybridization. *J Virol Methods* 1995;51:115-24.
  - 37 Ylitalo N, Bergström T, Gyllenstein U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. *J Clin Microbiol* 1995;33:1822-8.
  - 38 Cavuslu S, Starkey WG, Kaye JN, et al. Detection of human papillomavirus type-16 DNA utilising microtitre-plate based amplification reactions and a solid-phase enzyme-immunoassay detection system. *J Virol Methods* 1996;58:59-69.
  - 39 Jacobs MV, Snijders PJF, Adriaan JC, et al. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. *J Clin Microbiol* 1997;35:791-5.
  - 40 Morrison EAB, Goldberg GL, Kadish AS, et al. Polymerase chain reaction detection of human papillomavirus: quantitation may improve clinical utility. *J Clin Microbiol* 1992;30:2539-43.